MLA
CVS icon

MB, Levis & Associates’s CVS Health CVS Stock Holding History

MB, Levis & Associates’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.2K Buy
321
+2
+0.6% +$179 0.01% 128
2026
Q1 		$22.9K Buy
319
+3
+0.9% +$231 0.01% 136
2025
Q4 		$25.1K Buy
316
+3
+1% +$237 0.01% 133
2025
Q3 		$23.6K Buy
313
+3
+1% +$206 0.01% 134
2025
Q2 		$21.4K Buy
310
+3
+1% +$197 0.01% 165
2025
Q1 		$20.8K Buy
307
+3
+1% +$180 0.01% 160
2024
Q4 		$13.6K Buy
304
+4
+1% +$224 0.01% 175
2024
Q3 		$18.9K Sell
300
-328
-52% -$19.1K 0.01% 164
2024
Q2 		$37.1K Buy
628
+7
+1% +$438 0.02% 127
2024
Q1 		$49.5K Sell
621
-13
-2% -$993 0.03% 118
2023
Q4 		$50.1K Buy
634
+5
+0.8% +$356 0.03% 115
2023
Q3 		$43.9K Buy
629
+24
+4% +$1.7K 0.03% 117
2023
Q2 		$41.8K Buy
605
+5
+0.8% +$356 0.03% 126
2023
Q1 		$44.6K Hold
600
– – 0.03% 116
2022
Q4 		$55.9K Buy
+600
New +$57.9K 0.04% 100

Other funds holding CVS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

MB, Levis & Associates's CVS Position: Q2 2026 in Review

MB, Levis & Associates increased its CVS Health (CVS) stake by 0.63% in Q2 2026, buying an estimated $179 and bringing the position to 321 shares worth $33.2K. The position accounts for 0.01% of the portfolio, ranked #128.

MB, Levis & Associates first reported a position in CVS in Q4 2022 and has held it in 15 quarters since. The position peaked at $55.9K in Q4 2022. 2,069 funds tracked by Wall St. Rank hold CVS as of Q2 2026.

  • MB, Levis & Associates held 321 shares of CVS Health worth $33.2K as of Q2 2026.
  • MB, Levis & Associates bought 2 CVS Health shares in Q2 2026, an estimated $179.
  • CVS Health made up 0.01% of MB, Levis & Associates's portfolio in Q2 2026, its #128 holding.
  • MB, Levis & Associates first reported a position in CVS Health in Q4 2022 and has held it in 15 quarters since.
  • MB, Levis & Associates's CVS Health position peaked at $55.9K in Q4 2022.
  • 2,069 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.

Based on MB, Levis & Associates's 13F filing for Q2 2026, filed 22 Jul 2026.